Sichuan Kelun-Biotech Biopharmaceutical's (HKG:6990, SHE:002422) new indication application for TROP2 ADC sacituzumab tirumotecan was accepted for review by China's National Medical Products Administration.
The drug has been developed for the first-line treatment of patients with recurrent or metastatic triple-negative breast cancer, according to a Thursday Hong Kong bourse filing.
This is the sixth indication application accepted by the regulator for the product. The acceptance was based on positive results from a phase III registrational study.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments